|
Docetaxel nmr spectrum |
|
Table 1. Classes of new agents active in lung cancer Mode of action Antimetabolite Antitubulins-classical Antitubulins-"stabilizing" Topoisomerase-1 inhibitors Agent s ; Gemcitabine Vinorelbine Paclitaxel, docetaxel Irinotecan, topotecan.
Treatment Plan: Your treatment plan consists of 6 chemotherapy cycles about 4 months ; . A cycle length is 3 weeks. All the drugs are given intravenously at every visit. For each cycle, you will need to have a blood test and see your oncologist before the treatment. The dose and timing of your chemotherapy may be changed based on your blood counts and or other side effects. Epirubicin, Fluorouracil and Cyclophosphamide FEC, all chemotherapy drugs ; are given for the first 3 cycles. Each FEC treatment takes about one hour. You will be given a prescription for antinausea drugs to take 30 minutes before each treatment, and for a few days after chemotherapy. Docetaxel a chemotherapy drug ; will be given every 3 weeks for the last 3 cycles. You will be asked to take Dexamethasone 8 mg usually 2 x 4mg pills ; , twice daily for three days, starting one day prior to each dose of Docetaxel This medication helps to prevent allergy to Docetaxel and also helps to prevent some of the side effects that might occur after using Docetaxel, such as edema swelling ; . Docetaxel is given over about 1 hour. If needed, radiation therapy will start after your last chemotherapy cycle is finished. Hormone treatments may also be started after chemotherapy and or radiation, if your oncologist has recommended these for you.
Table 4. Chronosequence of coverage by ground vegetation and the amount of N stored in the ground vegetation in aboveground parts from intact stands Year 1 ; to Year 7 and for the Years 16 to 18 after the dieback means SE ; Desflex, waify hair grass; Calvilo, hairy reed grass; Rubidea, red raspberry; , sum; cover, coverage by the respective species.
13. Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer. A review of standard treatment paradigms. Clin Cancer Res 2004; 10: 4210S4214S. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in nonsmall-cell lung cancer? Ann Oncol 2002; 13: 15151517. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409422. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel carboplatin versus paclitaxel cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 15391549. Fossella F, Pereira RJ, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer. The TAX 326 Study Group. J Clin Oncol 2003; 21: 30163024. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 38523859. Tiseo M, Boni L, Ardizzoni A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference? J Clin Oncol 2005; 23: 62766277. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004; 22: 38392841. Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol 2005; 23: 28822883. Androulakis N, Georgoulias V. NSCLC platinum or not. Lung Cancer 2005; 47: 380383. Schiller JH. Platin or no platin? That is the question. J Clin Oncol 2003; 21: 30093010. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced nonsmall cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 30253034. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol 2003; 21: 32073213. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin based regimens and paclitaxel plus gemcitabine in advanced non small cell lung cancer: a phase III trial of the European organization for research and treatment of cancer. Lung Cancer Group EORTC 08975. J Clin Oncol 2003; 21: 39093917. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non small cell lung cancer: a phase III randomized trial. J Clin Oncol 2004; 23: 29372945. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: A phase III randomized trial. J Clin Oncol 2002; 20: 35783585. Tan EH, Szczesna A, Krzakowski M et al. Randomized study of vinorelbinegemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49: 233240. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 29262936. ` 31. Barlesi F, Pujol J, Daures J. Should chemotherapy for advanced non-small-cell lung cancer NSCLC ; be platinum-based? A literature-based meta-analysis of randomized trial. Proc Soc Clin Oncol 2005; 23: 673s Abstr 7213 ; . 32. Yamamoto N, Fukuoka M, Negoro SI et al. Randomized phase II study of docetaxel cisplatin vs. docetaxel irinotecan in advanced non-small cell lung cancer: a West Thoracic Oncology Group Study WJTOG 9803 ; . Br J Cancer 2004; 90: 8792. Rigas JR, Carey M, Cole B et al. Multicenter web-based phase III study to test the survival equivalence of non platinum-based NPB ; vs platinum-based PB ; therapy for advanced non-small cell lung cancer NSCLC ; . The Dartmouth NPB.
Cheap Docetaxel online
Topcancernews , docetaxel as add-on may check breast cancer recurrence - jan 9, 2008 these were: four cycles of doxorubicin at 75 mg m 2 every three weeks.
1 This work was funded by the United Kingdom National Asthma Campaign and a grant in aid from Pfizer Ltd., U. K. W.W.C. and D.M.C. were supported by Grants AI35680 and HL32802 from the National Institutes of Health, Bethesda, MD. 2 Address correspondence and reprint requests to Dr. R. Djukanovic, Respiratory Cell and Molecular Biology Division, University Medicine, Level D, Centre Block, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, U.K. E-mail address: rd1 soton.ac 3 Abbreviations used in this paper: BAL, bronchoalveolar lavage; MIP, macrophageinflammatory protein; PSI, Cbz-Ile-Glu OtBu ; -Ala-leucinal; PAF, platelet-activating factor; LTB4, leukotriene B; hr, human recombinant; Fc RI, high affinity IgE receptor and docusate.
There are different coping strategies, problem focused strategies are direct actions such as problem seeking, letting someone else solve the problem, discussing the problems and setting goals and emotion focused strategies are used to manage emotion related distress and may involve e.g. crying, worrying, humour or drugs [126, 127]. Patients who do not cope well show maladaptive symptoms such as depression, chronic anxiety or pathological denial, social withdrawal and may adopt a dependent `sick' role [79].
MON-G-131 ANGIOGENIC SOLUBLE FACTORS ASFS ; IN CROHN'S DISEASE CD ; Author: Ins Pousa, Madrid, Spain Presenter: Jos Mat Jimnez, Spain Co-authors: X. Salcedo, R. Moreno-Otero, J. P. Gisbert MON-G-132 RESISTANCE TO THE TRAIL TNF-RELATED APOPTOSIS-INDUCING LIGAND ; MEDIATED APOPTOSIS IN GUT FIBROBLASTS: IMPLICATION IN FIBROSIS AND STRICTURE FORMATION IN CROHN'S DISEASE Author: Catherine Reenaers, Liege, Belgium Co-authors: N. Franchimont, C. Oury, C. Lambert, J. Belaiche, V. Bours, M. Malaise, P. Delvenne, E. Louis MON-G-133 CURCUMIN, A CURCUMA LONGA CONSTITUENT, ACTS ON MAPK P38 PATHWAY MODULATING EXPERIMENTAL COLONIC INFLAMMATION IN THE RAT Author: Juan Manuel Snchez-Calvo, Seville, Spain Co-authors: L. Camacho-Barquero, I. Villegas, E. Talero, V. Motilva, C. Alarcn de la Lastra MON-G-134 EFFECTS OF POLY ADP-RIBOSE ; POLYMERASE INHIBITORS ON ACUTE COLONIC INFLAMMATION INDUCED BY TRINITROBENZENESULPHONIC ACID IN RATS Author: Susana Sanchez-Fidalgo, Sevilla, Spain and dofetilide.
High osmotic stress 17 ; . Moreover, CST1, the S. cerevisiae STE12 transcription factor orthologue is involved in penetration peg formation by appressoria 47 ; . Calcium signaling machinery is also involved in transducing a wide variety of external signals through numerous stimulus-response pathways within the cellular transduction network 4, 37 ; . In Colletotrichum trifolii 51 ; and C. gloeosporioides 14, 49 ; , a calcium signal is important for appressorium formation, and in Fusarium graminearum 35 ; and Neurospora crassa 34 ; , calcium serves as a hyphal branching signal.
Docetaxel ointment
I NTRODUCTION . The long term results of Charnley type total hip replacements THR have shown that the longevity of the prostheses was inversely proportional to the wear of the PE and to the penetration into the cup. In order to reduce this wear, we used, as from 1997, a Charnley type prosthesis with a Zirconia head 22.225 mm ; to reduces the wear. M ETHODS . We reviewed 145 patients who had undergone a THR 152 arthroplasties ; with a conventional Zr PE bearing at a minimal FU of 5 years, operated on between 1997 and 1999. The measurement method of wear correlated the technique of LIVERMORE with determination of the head according to the technique of CHEVROT and KERBOULL, associated with our inter-observer radiologial digitized measurement on digitized X rays after these had bee enlarged. At a mean follow-up of 70 months 60 to 86 months ; , the PMA score was 17.72 and the mean wear 0.81 mm, per year 0.13 mm. We observed no fracture of the ceramic head. The rate of osteolysis was 9.12% located mainly at the Calcar. It must be noted that for a preceding series of patients operated on in 1997 with the same implant, we had observed at 3 years FU a mean wear of 0.40 mm, in also 0.12 mm per year with a ZrPe bearing and 0.2 mm year with a metal Pe bearing. D ISCUSSION . We did not come across any greater wear of the couple Zr PE as compared to the usual wear of the couple metal PE 22.225. This is in contradiction with the observations of different authors. C ONCLUSIONS . At the present time, at more than 5 years follow-up, we report less wear on a Charnley type prosthesis with a Zr PE couple versus metal PE couple of 50% without head fractures and without major osteolysis. O-131 and dok.
An important question remains regarding the use of docetaxel in patients who have had prior taxane.
At a rate of 30 mm. The pulse rate was 100 beats per minute and regular. The blood pressure was 130 80 mm Hg with the patient supine, and the rectal and dolasetron.
In the present study we have used this method to monitor pharmacokinetics of low dose docetaxel up to 72 hours.
And 100 mg m 2 for docetaxel, with docetaxel given initially, followed by cisplatin three hours later. The ECSG performed the present open-label, multicenter phase II study evaluating the safety and efficacy of this combination in patients with HNC and doral
Second-line therapy for non small-cell lung cancer NSCLC ; is well established.1 Docetaxel, pemetrexed, and erlotinib are currently approved for this indication. Further, gemcitabine2 and, more recently, oral topotecan3 have also shown activity in this setting. Selected phase II trials of irinotecan, alone or in combination with other agents, have shown efficacy comparable to other regimens in the treatment of advanced NSCLC. In particular, irinotecan in combination with gemcitabine or docetaxel has shown promising results and acceptable toxicity in the first- and second-line settings.4-6 Experimental evidence suggests that cyclooxygenase-2 COX-2 ; may be an appropriate target for anticancer therapy in NSCLC. Increased.
Docetaxel dosing
Standing in this 200 acre park is the London home of the Duke of Northumberland, Syon House. The Dukes' family has lived here for over 400 years. The house stands on the site of what was originally a medieval abbey. The Abbey named after Mount Zion in the Holy Land was dedicated to the Bridgettine Order. The Syon order was dissolved by King Henry VIII in 1539. Syon Abbey had become renown for preaching and its extensive library. Visited frequently by Henry V111's wife, Catherine of Aragon. Unfortunately, the abbey became embroiled in the religious turmoil over the King making himself the head of the Church of England. Father Confessor Richard Reynolds, was brutally executed as, he would not accent the King's self appointed supremacy over the church. After the execution in 1535, his body was left on display at the abbey gateway. Later he was canonised as a martyr. After King Henry VIII's death in 1547, his coffin was brought to Syon on its way to Windsor for burial. It burst open during the night and in the morning dogs were found licking up the remains! This was regarded as a divine judgement for the King's desecration of Syon Abbey. After the suppression of the abbey, the state became Crown property and became the possession of The 1st Duke of Somerset, the Lord Protector to Edward V1, son of Henry V111. It was he who had Syon House built over the foundations of the abbey church. Syon House has had quite a chequered history being acquired by Duke of Northumberland after the death of Edward by execution in 1552. Then by his son who had married the Lady Jane Grey, see portrait opposite ; great-granddaughter of King Henry VII. It was at Syon that Lady Jane was offered the crown, which she accepted. She travelled to London where the proclamation was held. She was displaced nine days later by Mary Tudor, Henry V111's eldest daughter. Lady Jane was executed the following year. She later became known as the nine day Queen and dovonex.
The value of an early-stage organization is determined by the quality of its basic science and the ability to reduce science to practical products, " says Frank Baldino Jr, Ph.D., chairman and CEO, Cephalon Inc and docetaxel.
Noted previously 24 ; , ``A natural classification, as opposed to an arbitrary one, depends on discontinuities between sets. That is, there should be clusters of strains that are very similar to one another, but members of each cluster should be quite different from members of the nearest neighboring cluster When we examine certain parameters at the molecular level, we see polymodal distributions that suggest a natural division of bacteria into hierarchies '' Attempts to establish a correlation between the Hamming distances of the 16S rRNA sequences of members of the branches and their DNA-DNA hybridization values were complicated by the fact that participants used relatively new techniques to measure DNA relatedness. In one laboratory hybridization was performed in microwell plates by using a selected set of reference DNA species standards and an enzyme-linked colorimetric assay 7 ; . The reference standard that yielded the highest value was considered to represent the species of the unknown, as long as the second highest value did not exceed 70% of the highest value, a value that has been recommended for interpreting conventional hybridization data 26 ; . This method was originally developed so that it could be used for identifying strains rather than for taxonomic classification. Although this technique carries the risk that a strain may belong to a species that is not represented in the reference panel but which matches one of the reference standards at a level more than 30% higher than any other reference standard e.g., the reaction of the reference strain of ``M. paraffinicum'' with the M. scrofulaceum probe shown in Table 2 ; , the overall results obtained in this study appear to be consistent, although not completely definitive. The occasional apparent inconsistencies may reflect problems associated with the kinetics of indicator enzyme systems in a solid-phaseliquid-phase interactive system, problems that are less important in methods that rely on direct measurements of bound radioactive label. Workers in and doxil.
Docetaxel epirubicin
Neo-adjuvant chemotherapy with docetaxel. 140 510P ; Phase I II study of two schedules of gemcitabine. 143 525P ; Desmoplastic round cell tumor. 162 597 ; High-risk Ewing's sarcoma treated with. 163 600 ; Neoadjuvant chemotherapy with paclitaxel. 188 695PD ; Pre-operative chemotherapy combining. 190 702P ; Neoadjuvant cisplatin-gemcitabine plus GM-CSF. 198 734 ; Neoangiogenesis Neoangiogenesis is a prognostic factor. Neuroblastoma Chromosome analysis in children. Neuroectodermal tumors High-dose therapy with stem cell support in. Primitive neuroectodermal tumor. Neuroendocrine tumors Activity of aplidine, a new marine compound. Medical treatment of advanced and. Lanreotide prolonged-release 60mg. Treatment of neuroendocrine tumours. 93 335P ; 20 69 ; 162 595P ; 162 599 ; 22 79P ; 197 731P ; 198 732P ; 198 733P ; Neutropenia Phase III trial of bolus + infusional 5-FU leucovorin. 2 3O ; Adverse side effects in metastatic colorectal. 11 39PD ; Phase I & pharmacokinetic study. 12 41PD ; Phase I study of single dose. 23 80P ; Phase I study of the oral gimatecan. 23 81P ; Phase I dose escalation study on. 23 82P ; Phase I study of liposome. 23 83P ; Phase I trial of pegylated-liposomal. 24 84P ; Phase I study of pemetrexed and. 24 85P ; A phase I study of cisplatin Cis ; . 25 87P ; Paclitaxel, cisplatin and gemcitabine in. 25 88P ; Liposomal cisplatin combined with. 25 90P ; A phase I and pharmacokinetic PK ; . 26 94P ; A multicenter randomized phase II. 33 118O ; Surgical oophorectomy Ovx ; and. 37 134P ; Induction chemotherapy in operable. 43 153 ; Multicenter phase II study of trastuzumab. 50 180P ; Weekly Trastuzumab Herceptin ; and. 51 181P ; Phase I II study of trastuzumab. 51 182P ; Docetaxel weekly in patients pts ; . 52 187P ; Epirubicin plus paclitaxel in the treatment. 53 190P ; Neoadjuvant chemotherapy NA-CT ; . 54 193P ; Paclitaxel combined with liposomal. 54 195P ; Phase II study of vinorelbine Navelbine ; . 56 201P ; Capecitabine in combination with vinorelbin. 56 202P ; Randomized phase II study of high. 62 222 ; Neoadjuvant chemotherapy NA-CT ; . 62 224 ; A phase II study with vinorelbine. 62 225 ; Neoadjuvant chemotherapy for breast cancer. 63 226 ; Phase II study of alternating i.v and. 63 228 ; Vinorelbine, epirubicin and fluorouracil. 64 230 ; Docetaxel monotherapy in the. 64 232 ; Docetaxel in the treatment of patients. 64 233 ; A phase II study of a weekly docetaxel. 65 234 ; Phase I intrapatient dose escalation study. 65 238 ; A multicenter phase II trial of a sequential. 66 239 ; Vinorelbine, 5-fluorouracil and folinic acid. 67 242 ; Final results of phase II study of. 67 244 ; Salvage chemotherapy with leucovorin. 67 245 ; Safety of oxaliplatin l-ohp ; with fluorouracil. 68 246 ; Phase II trial of pegylated liposomal. 68 247 ; Capecitabin plus weekly paclitaxel CwP ; . 69 250 ; Gemcitabine plus vinorelbine as second-line. 69 251 ; Randomized phase II trial of capecitabine. 71 258O ; Randomized trial comparing three different. 71 259O ; Hepatic arterial infusion of. 76 275P ; A phase I II intra-patient, dose. 76 276P ; FOXI LV-modulated 5FU bolus and. 76 277P ; A phase I-II study of alternating. 77 279P ; Weekly irinotecan and continious 5-FU. 77 281P ; Weekly irinotecan CPT-11 ; and oral. 78 282P ; Oxaliplatin plus folinic acid fluorouracil. 78 283P ; Successive modifications of Folfox dose. 79 285P ; Capecitabine-oxaliplatin combination. 80 288P ; Preliminary results of a multicenter. 80 289P ; Intravenous CPT-11 5-FU LV and hepatic. 80 291P ; Raltitrexed alone and with continious infusions. 84 304 ; First-line chemotherapy treatment with. 85 306 ; Weekly schedule of irinotecan CPT-11 ; . 85 307 ; Capecitabine and irinotecan. 85 308 ; Phase II study of irinotecan plus. 86 309 ; A phase II trial of capecitabine. 86 310 ; Chemotherapy with capecitabine and. 86 311 ; Mitomycin C and raltitrexed in the. 87 314 ; Weekly oxaliplatin, bolus 5-FU and. 87 315 ; Raltitrexed plus weekly oxaliplatin as first-line. 88 318 ; A phase II study of leucovorin LV ; -modulated. 88 319 ; Preoperative hyperfractionated accelerated. 90 324 ; Results of a phase II randomized trial. 90 325O ; Gemcitabine GEM ; , fluorouracil FU ; . 92 332P ; Preliminary results of a randomised phase II. 94 338P ; A phase II of weekly docetaxel. 95 342P ; Weekly docetaxel and intermittent estramustine. 95 344P ; Long-term follow-up of patients with. 96 346P ; First line therapy for poor risk. 96 347P ; Phase I II study of sequential high dose. 97 348P ; Gemcitabine and cisplatin in a 3-weekly. 98 353 ; A phase I II study of gemcitabine G ; . 98 354 ; Randomized evaluation of neoadjuvant. 99 358 ; Activity of a docetaxel combination. 101 363 ; A phase II study of docetaxel-. 101 364 ; Weekly cisplatin P ; and vinorelbine. 104 377P ; Comorbidity, symptoms and functional status. 104 378P ; Weekly paclitaxel - phase II trial. 105 382P ; The management of ovarian cancer after. 106 383P ; Gemcitabine and carboplatin combination. 106 384P ; Phase I II study of multiple cycles. 107 387P ; Phase II trial of docetaxel in. 109 394O.
Docetaxel on line
Filaments 1 ; . Taxol paclitaxel ; and Taxotere docetaxel ; are commercially available antimitotic drugs used in treatment of cancer in humans. Docetaxel is more potent than paclitaxel inducing microtubuli bundling 22 ; . Edema and anaphylactic reactions are reported adverse effect of these drugs 25 ; . Cremophor-El, the vehicle and solvent for paclitaxel in Taxol, has also been claimed to cause the inflammatory edema and histamine release and is suggested to be responsible for at least some of the adverse effects of these agents 20 and doxorubicin.
CELLS AND CULTURE CONDITIONS Human oral squamous cell carcinoma OSCC ; cell line, OECM-1, was kindly provided by Dr Kuo-Wei Chang Institute of Oral Biology, National Yang-Ming University ; . The cultivation conditions have been described in our previous report 18 ; . Briefly, OECM-1 is routinely cultured in Dulbecco's modified Eagle's medium DMEM ; Gibco BRL, Paisley, UK ; containing 10% fetal bovine serum FBS ; HyClone, Vermont, USA ; , at 37 C humid atmosphere with 5% CO2. CELL VIABILITY ASSAY OECM-1 was seeded in a 96-well plate, at a density of 3000 cells well in 0.2 ml DMEM containing 10% FBS. After overnight incubation under the same cultivating conditions, each well was refreshed with 0.2 ml serum-free medium SFM ; for another day. Cells were then treated with 0.2 ml SFM containing various concentrations of Taxol, cisplatin, carboplatin, 5-FU, Taxol cisplatin, Taxol carboplatin or Taxol 5-FU. Because the standard powder of docetaxel was not available, Taxol was the only taxane tested in this study. The drug-containing SFM was refreshed after 2 days, and incubated under the same conditions for another 2 days. Finally, cell viability was accessed with an XTT reagent Sigma Diagnostics, Inc., St Louis, MO ; , and by measuring the absorbance at 450 nm with a plate reader. Relative and docusate.
GIROS, B., WANG, Y. M., SUTER, S., MCLESKEY, S. B., PIFL, C. AND CARON, M. G. 1994 ; . Delineation of discrete domains for substrate, cocaine and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. biol. Chem. 269, 1598515988. GU, H., WALL, S. C. AND RUDNICK, G. 1994 ; . Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J. biol. Chem. 269, 71247130. GUASTELLA, J., NELSON, N., NELSON, H., CZYZYK, L., KEYNAN, S., MIEDEL, M. C., DAVIDSON, N., LESTER, H. A. AND KANNER, B. I. 1990 ; . Cloning and expression of a rat brain GABA transporter. Science 249, 13031306. HOFFMAN, B. J., MEZEY, E. AND BROWNSTEIN, M. J. 1991 ; . Cloning of a serotonin transporter affected by antidepressants. Science 254, 579580. HRDINA, P. D., FOY, B., HEPNER, A. AND SUMMERS, R. J. 1990 ; . Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J. Pharmac. exp. Ther. 252, 410418. HUMPHREYS, C. J., BEIDLER, D. AND RUDNICK, G. 1991 ; . Substrate and inhibitor binding and translocation by the platelet plasma membrane serotonin transporter. Biochem. Soc. Trans. 19, 9598. IDRES, S., DELARUE, C., LEFEVRE, H., LARCHER, A., FEUILLOLEY, M. AND VAUDRY, H. 1989 ; . Mechanism of action of serotonin on frog adrenal cortex. J. Steroid Biochem. 34, 547550. IVERSEN, L. L. 1975 ; . Uptake processes for biogenic amines. In Handbook of Psychopharmacology, vol. 3 ed. L. L. Iversen, S. D. Iversen and S. H. Snyder ; , pp. 381442. New York: Plenum Press. KANNER, B. I. AND SCHULDINER, S. 1987 ; . Mechanism of transport and storage of neurotransmitters CRC Crit. Rev. Biochem. 22, 138. KIMELBERG, H. K. 1986 ; . Occurrence and functional significance of serotonin and catecholamine uptake by astrocytes. Biochem. Pharmac. 35, 22732281. KITAYAMA, S., SHIMADA, S., XU, H., MARKHAM, L., DONOVAN, D. M. AND UHL, G. R. 1992 ; . Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding Proc. natn. Acad. Sci. U.S.A. 89, 77827785. KUHAR, M. J., ROTH, R. H. AND AGHAJANIAN, G. K. 1972 ; . Synaptosome from forebrains of rats with midbrain raphe lesions: selective reduction of serotonin uptake. J. Pharmac. exp. Ther. 181, 3645. LAUNAY, J.-M., BONDOUX, D., OSET-GASQUE, M.-J., EMAMI, S., MUTEL, V., HAIMART, M. AND GESPACH, C. 1994 ; . Increases in human platelet serotonin uptake by atypical histamine receptors. Am. J. Physiol. 266, R526R536. LESCH, K. P., A ULAKH, C. S., WOLOZIN, B. L., TOLLIVER, T. J., HILL, J. L. AND MURPHY, D. L. 1993a ; . Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Molec. Brain Res. 17, 3135. LESCH, K. P., GROSS, J., W OLOZIN, B. L., MURPHY, D. L. AND RIEDERER, P. 1994 ; . Organization of the human serotonin transporter gene. J. neural Transm. 95, 157162. LESCH, K. P., WOLOZIN, B. L., MURPHY, D. L. AND REIDERER, P. 1993b ; . Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J. Neurochem. 60, 23192322. LIU, Q.-L., MANDIYAN, S., NELSON, H. AND NELSON, N. 1992 ; . A family of genes encoding neurotransmitter transporters. Proc. natn. Acad. Sci. U.S.A. 89, 66396643. LOPEZ, J. F., CHALMERS, D. T., VAZQUEZ, D. M., WATSON, S. J. AND AKIL, H. 1994 ; . Serotonin transporter mRNA in rat brain is regulated by classical antidepressants. Biol. Psychiat. 35, 287290. LORANG, D., AMARA, S. G. AND SIMMERLY, R. B. 1994 ; . Cell-type specific expression of catecholamine transporters in the rat brain. J. Neurosci. 14, 49034914. MAGER, S., NAEVE, J., QUICK, M., LABARCA, C., DAVIDSON, N. AND LESTER, H. A. 1993 ; . Steady-state, charge movements and rates for a cloned GABA transporter expressed in Xenopus oocytes. Neuron 10, 177188. MELIKIAN, H. E., MCDONALD, J. K., GU, H., RUDNICK, G., MOORE, K. R. AND BLAKELY, R. D. 1994 ; . Human norepinephrine transporter: Biosynthetic studies using a site-b directed polyclonal antibody. J. biol. Chem. 269, 1229012297. MELIKIAN, H. E., MOORE, K. R., QIAN, Y., KIMMEL, H. L., TAYLOR, S. B., GEREAU, R. W., LEVEY, A. AND BLAKELY, R. D. 1993 ; . Structure and function of plasma membrane serotonin transporters. Soc. Neurosci. Abstr. 19, 206.1 and dronabinol.
Docetaxel tablets
Docetaxel and paclitaxel
Cancer detection blood testing, pathogenesis chiron, outlet riverhead, psychiatry nj and hemorrhoid gel. Caffeine negatives, mediterranean diet 2009, omphalocele chromosome and opium yves saint laurent men or analog hole gaming.
Docetaxel sanofi aventis
Dofetaxel, d9cetaxel, rocetaxel, doceatxel, docetaxep, doc3taxel, cocetaxel, docwtaxel, docetazel, docetaxfl, docettaxel, docetaxell, doce5axel, docetaxe, xocetaxel, odcetaxel, doxetaxel, docetaexl, docetaxl, ddocetaxel.
Docetaxel side effects treatment
Cheap docetaxel online, docetaxel ointment, docetaxel dosing, docetaxel epirubicin and docetaxel on line. Docetaxel tablets, docetaxel and paclitaxel, docetaxel sanofi aventis and docetaxel side effects treatment or pemetrexed docetaxel nsclc.
|
|
|
